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TIMP-2Matrix metalloproteinases (MMP) are involved in the disruption of blood–brain barrier (BBB) during migraine
attacks. In the present study, we hypothesized that two functional polymorphisms (C−1306T and C−735T) in
MMP-2 gene and MMP-2 haplotypes are associated with migraine and modify MMP-2 and tissue inhibitor of
MMP (TIMP)-2 levels in migraine. Genotypes for MMP-2 polymorphisms were determined by real time-PCR
using Taqman allele discrimination assays. Haplotypes were inferred using the PHASE program. Plasma
MMP-2 and TIMP-2 concentrations were measured by gelatin zymography and ELISA, respectively, in 148
healthy women without history of migraine and in 204 women with migraine (153 without aura; MWA, and
51 with aura; MA). Patients with MA had higher plasma MMP-2 concentrations and MMP-2/TIMP-2 ratios
than patients with MWA and controls (Pb0.05). While MMP-2 genotype and haplotype distributions for the
polymorphisms were similar among the groups (P>0.05), we found that the CC genotype for C−735T polymor-
phism and the CC haplotype were associated with higher plasma MMP-2 concentrations in MA group (Pb0.05).
Our ﬁndings may help to understand the role of MMP-2 and its genetic variants in the pathophysiology of mi-
graine and to identify a particular group of migraine patients with increased MMP-2 levels that would beneﬁt
from the use of MMP inhibitors.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Migraine is a common, complex, disabling, neurovascular disorder
affecting approximately 10% of the adult population worldwide, espe-
cially women (Jensen and Stovner, 2008). Special attention should be
given to this clinical disorder becausewomenwithmigraine, particular-
ly those with aura, are exposed to an increased risk of cardiovascular
diseases including ischemic stroke (Bigal et al., 2010; Rist et al., 2010).
Although the underlying etiology of this condition remains unknown,
cortical spreading depression (CSD), plasma protein extravasation,
and neurogenic inﬂammation are mechanisms involved in the patho-
physiology of migraine (Galletti et al., 2009; Pietrobon and Striessnig,
2003). In this respect, mounting evidence suggests that matrix
metalloproteinases (MMP) may alter the vascular permeability of
cerebral vessels and disrupt blood–brain barrier (BBB), thus leading toB, Blood–brain barrier; TIMPs,
ssion; MWA, Migraine without
merase chain reaction; ELISA,
, Faculty of Medicine of Ribeirao
9-900 Ribeirao Preto, SP, Brazil.
ahoo.com (J.E. Tanus-Santos).
vier OA license.a migraine attacks (Ashina et al., 2010; Bernecker et al., 2011;
Gursoy-Ozdemir et al., 2004;Martins-Oliveira et al., 2009). Importantly,
increased circulating MMP-2 concentrations were shown in patients
with migraine (Martins-Oliveira et al., 2009).
MMPs are a large family of zinc-dependent endopeptidases involved
in the degradation of many components of the extracellular matrix
(Sbardella et al., 2012). Accordingly, MMP activity is regulated at the
levels of gene transcription, post-translational modiﬁcations, and by in-
teractions with their endogenous inhibitors, the tissue inhibitors of
MMPs (TIMPs) (Fontana et al., 2012). Because an imbalance between
MMP-2 and its endogenous inhibitor (TIMP-2) contributes to several
pathologic conditions affecting both the cardiovascular and the central
nervous systems (Ceron et al., 2012; Heo et al., 1999; Marson et al.,
2012; Palei et al., 2012; Rosenberg, 2009), MMP inhibition has been
suggested as an attractive therapeutic target in prevention of such dis-
eases (Castro et al., 2011; Romi et al., 2012). Importantly, TIMP-2 is
the most relevant MMP-2 inhibitor (Raffetto and Khalil, 2008) and
therefore the study of circulating MMP-2/TIMP-2 ratio may be useful
to assess reﬂect net MMP-2 activity in clinical studies, and therefore
changes in TIMP-2 levels may increase MMP-2 activity favoring disease
conditions.
Functional single nucleotide polymorphisms in the promoter re-
gion of the MMP-2 gene (the C−1306T/rs243865 and the C−735T/
36 F.M. Gonçalves et al. / Gene 512 (2013) 35–40rs2285053) affect MMP-2 expression or activity (Price et al., 2001; Yu
et al., 2004) and may predispose to disease conditions (Lacchini et al.,
2012; Saracini et al., 2012; Zhou et al., 2005), especially in those
subjects carrying MMP-2 variants associated with increased MMP-2
concentrations (Jacob-Ferreira et al., 2011; Marson et al., 2012). How-
ever, no previous study has examined how MMP-2 gene polymor-
phisms affect MMP-2 concentrations in patients with migraine.
This study aimed at determining whether functional MMP-2 poly-
morphisms are associated with migraine, and whether MMP-2 poly-
morphisms affect MMP-2 concentrations in patients. Furthermore,
because the analysis of combinations of genetic markers in a region
of interest (haplotypes) may provide an improved genetic informa-
tion (Crawford and Nickerson, 2005), the possibility thatMMP-2 hap-
lotypes affect the circulating MMP-2 and TIMP-2 levels, and MMP-2/
TIMP-2 ratio (a better index of net MMP-2 activity) in migraine pa-
tients was also examined.
2. Materials and methods
2.1. Study population
This study was approved by the Ethics Committee at Faculty of
Medicine of Ribeirao Preto, University of Sao Paulo, Brazil, and each
subject provided written informed consent.
This study included 204 women with migraine enrolled at the
Headache Clinic of the Division of Neurology, University Hospital of
the Faculty of Medicine of Ribeirao Preto, and 148 healthy women
without history of migraine. Among patients, 153 women were diag-
nosed with migraine without aura (MWA) and 51 with migraine with
aura (MA). All study subjects underwent a complete medical history
and physical examination. Diagnosis of migraine was made according
to the International Classiﬁcation of Headache Disorders criteria
(2004). The control group included healthy women without head-
ache randomly selected from the local population, unrelated to the
patients. Furthermore, women with other diseases including inﬂam-
matory diseases, pregnant, or with other kinds of headache were ex-
cluded from the study.
After written, informed consent was obtained, venous blood sam-
ples were collected into vacutainer plastic tubes containing sodium/
potassium EDTA. Blood samples were centrifuged at 1000 ×g for
10 min. Plasma samples were separated and immediately stored at
−70 °C until used to measure plasma MMP-2 and TIMP-2 concentra-
tions. In addition, aliquots of whole blood were separated and stored
at −20 °C for genomic DNA extraction.
2.2. DNA isolation and genotype determination
Genomic DNA was extracted from the cellular component of 1 mL
of whole blood through salting-out method and stored at −20 °C
until analyzed.
Genotypes for the C−1306T (rs243865) and the C−735T (rs2285053)
polymorphisms in the 5’-ﬂanking region of MMP-2 gene were deter-
mined by real time-polymerase chain reaction (RT-PCR), using Taqman
Allele Discrimination assays (Applied Biosystems, Carlsbad, CA, USA).
Probes and primers used for the C−1306T genotyping assay were cus-
tomized as follows: forward 5′-GCCATTGTCAATGTTCCCTAAAACA-3′,
reverse 5′-TGACTTCTGAGCTGAGACCTGAA-3′ and probes 5′-CAGC
ACTC[T/C]ACCTCT-3′. TaqMan PCR was performed in a total volume of
12 μl (3 ng of DNA, 1× TaqMan master mix, 1× assay mix) placed in
96-well PCR plates. Fluorescence from PCR ampliﬁcation was detected
using Chromo 4 Detector (Bio-Rad Laboratories, Hercules, CA, USA)
and analyzed with manufacturer's software. Probes and primers
used in MMP-2 C−735T assay were designed by Applied Biosystems
(ID: C_26734093-20). TaqMan PCR and ﬂuorescence reading were
performed as described above for the C−1306T polymorphism
(Lacchini et al., 2012).2.3. Determination of plasma MMP-2 by SDS-PAGE gelatin zymography
To investigate the effects of MMP-2 polymorphisms or haplotypes
on the circulating levels of MMP-2, gelatin zymography of MMP-2
from plasma samples was performed as previously reported
(Gerlach et al., 2007). Brieﬂy, plasma samples were diluted in sample
buffer (2% SDS, 125 mM Tris–HCl; pH 6.8, 10% glycerol and 0.001%
bromophenol blue) and subjected to electrophoresis on 7% SDS-
PAGE co-polymerized with gelatin (1%) as the substrate. After elec-
trophoresis the gel was incubated for 1 h at room temperature in a
2% Triton X-100 solution, and incubated at 37 °C for 16 h in Tris–
HCl buffer, pH 7.4, containing 10 mM CaCl2. Gels were stained with
0.05% Coomassie brilliant blue G-250, and then unstained with 30%
methanol and 10% acetic acid. Gelatinolytic activities were detected
as unstained bands against the background of Coomassie blue-
stained gelatin, by densitometry using ImageJ Program (National In-
stitutes of Health, USA). MMP-2 was identiﬁed as a band at 72 kDa
by direct comparison with relative mobility of Sigma SDS-PAGE
LMW marker proteins. The intensity value for the MMP-2 band was
calculated as relative activity according to the intensity of related
MMP-2 standard (Gerlach et al., 2007).
2.4. Enzyme immunoassay of TIMP-2
Plasma TIMP-2 concentrations were measured in EDTA-plasma,
using commercially available enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to
manufacturer's instructions. The reaction was evaluated using a
μQuant™ microplate reader (Bio-Tek Instruments Inc., Winooski, VT,
USA). Moreover, we calculated the MMP-2/TIMP-2 ratio because this
ratio may be a better index of net MMP-2 activity (Martins-Oliveira
et al., 2009).
2.5. Haplotype inference
Haplotypes were inferred using the Bayesian statistical based pro-
gram PHASE version 2.1 (Stephens et al., 2001) (http://www.stat.
washington.edu/stephens/software.html) to estimate the haplotype
frequencies in the population and the most likely pairs of haplotypes
for each individual. The possible haplotypes including genetic vari-
ants of two polymorphisms in the MMP-2 gene studied, C−1306T
and C−735T were: H1 (CC); H2 (CT); H3 (TC); H4 (TT). However,
due to low frequency of the H4 haplotype, we excluded it from the
analysis.
To assess differences in haplotype frequency distributions was
used χ2 test, and to compare haplotype frequencies in controls and
migraine a value of Pb0.0125 (0.05/4 — number of possible haplo-
types) was considered signiﬁcant to correct for the number of com-
parisons made.
2.6. Statistical analyses
The clinical data of study participants were compared by the
Kruskall–Wallis test followed by the Dunn's multiple comparison
test. The results were expressed as mean±standard deviation. The
categorical variables were compared by Fisher's exact test or χ2 test
and expressed as frequencies and percentages (StatView, Cary, NC,
USA). A value of Pb0.05 was considered to be statistically signiﬁcant.
The distribution of genotypes for each polymorphism was
assessed for deviation from the Hardy–Weinberg equilibrium, and
differences in the genotypic and alleles frequencies of each polymor-
phism between the groups were also assessed using χ2 tests. Due to
the relatively low frequency of the TT genotype for both MMP-2 poly-
morphisms, the CT and TT genotypes (CT+TT group) were com-
bined. To compare the effect of MMP-2 genotypes on circulating





















































37F.M. Gonçalves et al. / Gene 512 (2013) 35–40Student's test (normally distributed variables) or Mann–Whitney test
(not normally distributed variables) were used. A value of Pb0.05
was considered the minimum level of statistical signiﬁcance.
In addition, to examine whether MMP-2 haplotypes affect the cir-
culating levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 ratios, the
Kruskall–Wallis test followed by Dunn's Multiple Comparison test
(non-parametric data) or ANOVA followed by Tukey's test (parametric
data) were used.
3. Results
The data regarding clinical characteristics of subjects included in
the present study are summarized in Table 1. There were no signiﬁ-
cant differences in the clinical parameters among groups (P>0.05;
Table 1). Higher MMP-2 levels were found in patients in the MA
group compared with the MWA group (Pb0.05; Table 1). Lower
TIMP-2 levels were found in both MA and MWA groups compared
with controls (Pb0.05; Table 1). These differences resulted in higher
MMP-2/TIMP-2 ratios in MA and MWA groups compared with con-
trols, and higher MMP-2/TIMP-2 ratios in the MA group compared
with the MWA group (both Pb0.05; Table 1).
The results showing MMP-2 single-locus analysis and haplotypes
distributions in the groups are shown in Supplementary Table 1 and
Supplementary Table 2, respectively. The distribution of genotypes
for the two MMP-2 polymorphisms showed no deviation from
Hardy–Weinberg equilibrium (all P>0.05). No signiﬁcant differences
in the genotype and allelic distribution for the two MMP-2 polymor-
phisms were found when patients and controls were compared (all
P>0.05; Supplementary Table 1). In line with these results, no signif-
icant differences in the distribution ofMMP-2 haplotypes frequencies
among groups were found (all P>0.05; Supplementary Table 2).
The inﬂuence of the C−1306T and the C−735T MMP-2 polymor-
phisms on plasmaMMP-2, TIMP-2, andMMP-2/TIMP-2 ratios was de-
termined in the three study groups (Figs. 1 and 2). While no major
effects of genotypes for the C−1306T polymorphism on plasma
MMP-2 levels in migraine patients were found (P>0.05; Fig. 1A),
lower MMP-2 levels were found in controls with the CT or TT geno-
types compared with controls with the CC genotype (Pb0.05;
Fig. 1A). Moreover, higher MMP-2 concentrations were found in MATable 1
Clinical characteristics of study participants.
Parameters Control (N=148) MWA (N=153) MA (N=51)
Age (years) 36.9±11.7 38.2±11.5 39.5±10.6
BMI (kg/m2) 25.7±5.3 26.6±5.8 25.9±5.8
Ethnicity (%white) 70 62 58
Familial history (%) – 68 80
Frequency (%)
1–3/months – 11 14
3–5/months – 17 8
5–10/months – 12 26
10–15/months – 25 18
>15/months – 35 34
Intensity (%)
Mild – 0 4
Moderate – 33 26
Severe – 67 70
Duration (%)
b12 hours – 15 14
12–24 hours – 19 14
>24 hours – 66 72
Headache free (%) – 53 56
MMP-2 (A.U.) 0.99±0.39 0.96±0.38 1.16±0.39⁎,#
TIMP-2 (ng/ml) 115.0±28.3 95.4±18.1⁎ 92.5±19.0⁎
MMP-2/TIMP-2 0.0089±0.004 0.0102±0.004⁎ 0.0131±0.005⁎,#
MWA, migraine without aura; MA, migraine with aura; BMI, body mass index. A.U.,
arbitrary units; Values are the mean±S.D. or % number of subjects.
⁎ Pb0.05 vs. Control group.
# Pb0.05 vs. MWA group.










Fig. 1. Plasma MMP-2 (Panel A) and TIMP-2 (Panel B) concentrations, and MMP-2/
TIMP-2 ratios (Panel C) in controls (C), in women with migraine without aura
(MWA), and in women with migraine with aura (MA) with different MMP-2 geno-
types for the C−1306T polymorphism. The box and whiskers plots show range and
quartiles. The boxes extend from the 25th percentile to the 75th percentile, with a
line at the median. The whiskers show the highest and the lowest values. *Pb0.05 vs.
the respective C group. #Pb0.05 vs. the respective MWA group. **Pb0.05 vs. C group
with CC genotype.patients with the CC genotype than in MWA patients with the same
genotype (Pb0.05; Fig. 1A). Lower TIMP-2 levels were found in
the MWA and MA groups, independently of their genotypes for the
C−1306T polymorphism (both Pb0.05; Fig. 1B). While higher
MMP-2/TIMP-2 ratio were found in MA patients with the CC geno-
type compared with MWA or controls with the same genotype
(both Pb0.05; Fig. 1C), higher MMP-2/TIMP-2 ratios were found in
MWA and MA with CT and TT genotypes than in controls with the
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Fig. 2. Plasma MMP-2 (Panel A) and TIMP-2 (Panel B) concentrations, and MMP-2/
TIMP-2 ratios (Panel C) in controls (C), in women with migraine without aura
(MWA), and in women with migraine with aura (MA) with different MMP-2 genotypes
for the C−735T polymorphism. The box and whiskers plots show range and quartiles.
The boxes extend from the 25th percentile to the 75th percentile, with a line at the me-
dian. The whiskers show the highest and the lowest values. *Pb0.05 vs. the respective C
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Fig. 3. Plasma MMP-2 (Panel A) and TIMP-2 (Panel B) concentrations, and MMP-2/
TIMP-2 ratios (Panel C) in controls (C), in women with migraine without aura
(MWA), and in women with migraine with aura (MA) with different MMP-2 haplo-
types. The box and whiskers plots show range and quartiles. The boxes extend from
the 25th percentile to the 75th percentile, with a line at the median. The whiskers
show the highest and the lowest values. *Pb0.05 vs. the respective C group. #Pb0.05
vs. the respective MWA group. **Pb0.05 vs. MA group with CC (H1) haplotype.
38 F.M. Gonçalves et al. / Gene 512 (2013) 35–40With respect to the C−735T polymorphism, higher MMP-2 concen-
trations were found in MA patients with the CC genotype when com-
pared with MWA patients and controls with the same genotype
(Pb0.05; Fig. 2A). Interestingly, higher MMP-2 levels were found in
MA patients with the CC genotype than in MA patients with the CT
or TT genotypes (Pb0.05; Fig. 2A). Lower TIMP-2 levels were found
in MWA or in MA patients than in controls, independently of geno-
types (Pb0.05; Fig. 2B), and MA patients with the CT or TT genotypes
had lower TIMP-2 levels than MA patients with the CC genotype(Pb0.05; Fig. 2B). Higher MMP-2/TIMP-2 ratios were found in MA
or in MWA patients with the CC genotype (Pb0.05), but not with
the CT and TT genotypes (Fig. 2C).
The analysis of MMP-2 haplotypes showed higher plasma MMP-2
levels in MA patients with the CC (H1) haplotype compared with
MWA and controls with the same haplotype (Pb0.05; Fig. 3A). Pa-
tients with MA and the CT (H2) haplotype had lower MMP-2 levels
39F.M. Gonçalves et al. / Gene 512 (2013) 35–40when compared with MA patients and the CC (H1) haplotype
(Pb0.05; Fig. 3A). Higher MMP-2 levels were found in MA patients
with the TC (H3) haplotype compared with controls with the same
haplotype (Pb0.05; Fig. 3A). Interestingly, lower TIMP-2 levels were
found in MWA and in MA groups compared with controls indepen-
dently of their haplotypes (all Pb0.05; Fig. 3B). Higher MMP-2/
TIMP-2 ratios were found in MWA and in MA groups compared
with controls carrying either the CC (H1) or the TC (H3) haplotype
(both Pb0.05; Fig. 3C), but not in subjects carrying the CT (H2) hap-
lotype (Fig. 3C).
A power calculation analyses was performed using the Power for
Genetic Association Analyses (PGA) software (http://dceg.cancer.
gov/bb/tools/pga/). Given the sample size of this study, we obtained
a statistical power of 80% with an alpha of 0.05 to detect a relative
risk of 1.7 and 2.2 for the migraine total group (MWA andMA groups)
and for the MA group, respectively.
4. Discussion
To our knowledge, this is the ﬁrst study to show that functional
MMP-2 polymorphisms and haplotypes affect the circulating MMP-2
levels or MMP-2/TIMP-2 ratios in patients with migraine. While no
signiﬁcant associations between MMP-2 genetic polymorphisms or
haplotypes and migraine were found, the variations in MMP-2 and
MMP-2/TIMP-2 ratios associated with different MMP-2 genotypes
and haplotypes show that these MMP-2 polymorphisms affect rele-
vant features of the disease. Given the relevance of MMP-2 levels in
plasma, patients with higher MMP-2 levels associated with particular
genotypes or haplotypes may be exposed at increased risk of cardio-
vascular complications.
Despite the fact thatMMP-2has been associatedwith changes in the
BBB integrity in several pathologic conditions affecting the central ner-
vous system (Feng et al., 2011; Liu et al., 2012; Yang and Rosenberg,
2011; Yang et al., 2007), MMP-dependent mechanisms involved in
the disruption of BBB duringmigraine attacks have not been fully eluci-
dated (Edvinsson and Tfelt-Hansen, 2008). However, previous studies
suggest that CSD-relatedMMP activationmay enhance cerebrovascular
permeability and alter the BBB composition and function, thus generat-
ing a neuroinﬂammatory microenvironment that results in migraine
symptoms (Gursoy-Ozdemir et al., 2004). Giving support to this sugges-
tion, increasedMMP-2 levels andMMP-2/TIMP-2 ratios (which indicate
increased net MMP-2 activity) were found in women with migraine
with aura, thus providing evidence for the increased netMMP-2 activity
in those patients. Since abnormal MMP-2 activity clearly contributes to
vascular dysfunction and may increase the incidence of cardiovascular
events (Ceron et al., 2012; Dhillon et al., 2010; Ehrlich et al., 2011) we
could speculate that this particular group of migraine patients may be
exposed at higher risk of developing cardiovascular disease, especially
those with genotypes or haplotypes associated with increased MMP-2
levels. In fact, recent epidemiological studies reported an association
of migraine with aura not only with coronary events but also with is-
chemic stroke (Bigal et al., 2010; Kurth et al., 2012; Rist et al., 2010),
and growing evidence implicates MMP-2 in neuronal injury resulting
in BBB disruption, cerebral edema, and hemorrhage during the early
phase of ischemic stroke (Rosenberg et al., 1998; Yang and Rosenberg,
2011). Moreover, MMP activity inhibition is effective in preserving
BBB function and attenuates brain damage in the animal stroke models
(Rosenberg et al., 1992;Wang et al., 2012; Yang et al., 2007). Therefore,
our ﬁndings may have clinically relevant implications.
Because MMP-2 plays a central role in the degradation of extracel-
lular matrix components, both in physiological and in pathophysio-
logical conditions (Castro et al., 2011; Sbardella et al., 2012), there
is growing interest in examining whether polymorphisms in the
MMP-2 gene are associated with differences in MMP-2 levels
(Jacob-Ferreira et al., 2011; Lacchini et al., 2012; Marson et al.,
2012; Palei et al., 2012). Interestingly, the allele −1306T or −735Tdisrupts a Sp-1 binding site within the promoter region of MMP-2
gene, thus leading in lower MMP-2 promoter activity (Price et al.,
2001; Yu et al., 2004). These observations support our ﬁndings show-
ing that womenwith migraine with aura carrying the CC genotype for
C−735T polymorphism have increased MMP-2 levels compared with
those carrying the T allele.
A previous study showed that the MMP-2 haplotype combining
the C alleles for both polymorphisms is associated with increased
MMP-2 promoter activity and mRNA expression (Yu et al., 2004). In
line with this previous report, higher MMP-2 concentrations were
found in women with migraine with aura carrying the CC haplotype.
Although the molecular mechanisms explaining how patients with
aura carrying the CC haplotype have higher MMP-2 levels are not
clariﬁed by our ﬁndings, we could speculate that increased MMP-2
levels may predispose to migraine attacks resulting of impaired BBB
integrity. Furthermore, our ﬁndings may be clinically relevant be-
cause they may help to identify of a particular group of patients
with migraine that would beneﬁt from the use of MMP inhibitors.
However, this issue would require a clinical trial and it would be in-
teresting to replicate the present ﬁndings in different populations. It
is also possible that other drugs used in the therapy of other disease
conditions (Ceron et al., 2010; Sousa-Santos et al., 2012) may
downregulate MMP-2 levels and therefore exert beneﬁcial effects in
migraine patients.
This study has some limitations. Migraine is more frequently
found in women than in men (Jensen and Stovner, 2008). One limita-
tion of the present study is that we have studied only women, and
therefore our ﬁndings may not be extrapolated to men. In addition,
differences between populations (Lacchini et al., 2010) may also af-
fect the contribution of MMPs polymorphisms to migraine. Further
studies should address those issues. Although this study has statisti-
cally signiﬁcant ﬁndings, it would be interesting to carry out studies
with bigger sample size. Finally, only two polymorphisms in the pro-
moter region of MMP-2 gene were included in the present study. Al-
though these polymorphisms are functional, other polymorphisms
should be considered in future studies.
In conclusion, despite the lack of signiﬁcant association between ge-
notypes or haplotypes for theMMP-2polymorphisms andmigraine sus-
ceptibility, we found that functional MMP-2 polymorphisms and
haplotypes affect the circulatingMMP-2 levels or MMP-2/TIMP-2 ratios
in patients withmigraine. Our ﬁndings offer biochemical evidence for a
possible inﬂuence ofMMP-2 polymorphisms in the pathogenesis of mi-
graine, particularly with aura. These ﬁndings may have relevant impli-
cations in clinical practice with respect to the possible use of MMP
inhibitors when they become available for clinical use.
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